Progressive Pulmonary Fibrosis in China: A Nationwide Registry

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a nationwide, multicenter, prospective registry enrolling adults with progressive pulmonary fibrosis in China. Participants will be observed for up to 2 years to track changes in lung function and clinical characteristics, with data collection on treatments and unmet needs. The primary endpoint is the change in FVC (in milliliters) at 1 and 2 years, while secondary aims explore disease progression, treatment patterns, and patient needs in routine clinical care. Eligible participants must meet the 2022 ATS/ERS/JRS/ALAT PPF criteria and provide informed consent. Exclusion criteria include IPF diagnosis, absence of baseline HRCT, or concurrent participation in other drug trials.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Diagnosis of PPF within the past year, according to the 2022 ATS/ERS/JRS/ALAT guidelines;
2. Patients who are willing to participate in the study and have signed an informed consent form.

Exclusion Criteria:

1. Patients diagnosed with IPF.
2. Patients without baseline chest HRCT.
3. Patients who refuse to sign the informed consent form.
4. Patients participating in other clinical trials for medications. (Patients who have completed other trials or are in an unblinded phase after a washout period of 2 weeks are eligible for enrollment.)

Where it's running

• Peking Union Medical College Hospital
  Beijing, China Recruiting

Study contacts

• Study coordinator: Zuojun Xu Zuojun Xu
• Email: xuzi@hotmail.com
• Phone: +86 13671345136

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Nerandomilast in IPF and Progressive Fibrosis: Real-World Data

  This study tests whether nerandomilast helps slow lung function decline in adults with IPF or progressive fibrotic lung disease in routine clinical care.

  Recruiting at 4 sites Tel Aviv Medical Center · Ashkelon and 3 other locations · NCT07919015

• Inspiratory Flow Rate Capability in Pulmonary Fibrosis Patients

  This observational study tests how fast patients with IPF or PPF can inhale through dry powder inhalers with different resistances.

  Recruiting Shanghai Pulmonary Hospital, Shanghai, China · Shanghai, Shanghai Municipality · NCT07820254

• Treprostinil Palmitil Inhalation Powder for Progressive Pulmonary Fibrosis

  A 52-week study will test whether once-daily Treprostinil Palmitil Inhalation Powder helps lung function in adults with progressive pulmonary fibrosis compared to placebo.

  Recruiting Phase 3 Insmed Incorporated · DuBois, Pennsylvania · NCT07805785

• Finger vs. Earlobe Pulse Oximetry During a 6-Minute Walk Test in ILD

  This study tests whether finger or earlobe pulse oximetry gives the same oxygen saturation readings during a 6-minute walk in people with interstitial lung disease.

  Recruiting Hospital de Granollers · Granollers, Spain · NCT07723872

• Quercetin supplementation for people with fibrotic interstitial lung disease

  This research will try whether taking 500 mg/day of quercetin in two 12-week cycles can change telomere length, reduce signs of cellular aging, and affect lung function in people with IPF and other fibrotic interstitial lung diseases.

  Recruiting University of Crete · Heraklion, Crete · NCT07466420

• Measuring body fat and thigh muscle in people with pulmonary fibrosis starting anti-fibrotic drugs

  This project will test whether quick bioelectrical impedance measurements and thigh muscle ultrasound can detect changes in body fat and muscle in adults with IPF or progressive pulmonary fibrosis who are starting anti-fibrotic medications.

  Recruiting Royal Brompton & Harefield NHS Foundation Trust · London · NCT07332117

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.